Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
NCT05375825 · National Cancer Institute (NCI) · PHASE1 · withdrawn · last registry update 2024-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants enrolled.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MSLN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Anetumab Ravtansine + Pembrolizumab (NCT03126630)
- 2024-04-16Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + pembrolizumab (NCT04027946)
- 2024-02-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2024-02-02Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2023-08-04Results posted on the registry: Bayer, BAY94-9343 (Anetumab ravtansine) (NCT03926143)
- 2023-08-04Also stopped (terminated): Bayer, BAY94-9343 (Anetumab ravtansine) (NCT03926143)
- 2023-07-18Results posted on the registry: National Cancer Institute (NCI), LMB-100 + pembrolizumab (NCT04027946)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision